Bladder Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

London, United Kingdom (PressExposure) January 06, 2010 -- GlobalData’s analysis finds that the global bladder cancer market was worth $445m in 2009. It is expected to grow to $601m by 2016 at a Compound Annual Growth Rate (CAGR) of 4.4%. This growth is primarily attributed to the increased incidence and high recurrence rates among the patient population that is expected in the future. The growth will be further supported by the increased uptake of combination chemotherapy regimes and would witness a shift in the current gold standard treatment from MVAC to GemCis. A definite market leader in the current bladder cancer market cannot be identified, but there are numerous companies which have the potential to dominate the market in the future. Enhanced safety and efficacy profiles, coupled with cost effectiveness and patient compliance would be the key determining factors for the success of new therapies.

For further details, please click or add the below link to your browser:

GlobalData analyzed the current competition in the bladder cancer market to be weak due to the lack of efficacious and cost effective drugs in the market. Compared to other oncology therapeutic markets, the bladder cancer market has witnessed almost no new product entries for almost two decades. There is increased competition among the combination chemotherapies that are currently being tried in patients under pre-operative and post operative stages. Chemotherapy is the preferred first line treatment for most cases in the early stages of bladder cancer. However, high maintenance costs coupled with hospitalization and drug administration costs (since most are given by an intravesical route) for the indication has made it one of the most expensive forms of cancer to treat across the world.

For further details, please click or add the below link to your browser:

GlobalData analyzed that the available treatment options are moderately successful in fulfilling the market demand. Current modes of treatment are directed only at preventing the proliferation of bladder cancer instead of reducing the chances of remission and improving the quality of life in patients. For patients in later stages of the cancer, surgical removal of the bladder (in parts or as a whole) remains the only available option. However, safety remains a concern even in these cases. For people in the early stages, there is still a need for better therapy. There is a latent market potential for any new entrant that can cater to these high unmet needs. It should fulfill the basic requirements - a well established safety profile, affordability and better patient compliance. There is a lucrative opportunity for drugs that can offer a good recovery profile or those that can offer efficacy similar to the existing drugs but with a better safety profile.

GlobalData, the industry analysis specialist’s new report, “Bladder Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global bladder cancer market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Bladder cancer sector.

For further details, please click or add the below link to your browser:

Or visit our report store:

About GlobalData

GlobalData is a global market intelligence services company providing information research and analysis products and services.

Press Release Source:

Press Release Submitted On: January 06, 2010 at 3:28 am
This article has been viewed 14998 time(s).